CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 262 filers reported holding CLOVIS ONCOLOGY INC in Q3 2017. The put-call ratio across all filers is 0.57 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $43,000 | -56.6% | 36,350 | -33.8% | 0.00% | -66.7% |
| Q2 2022 | $99,000 | -49.0% | 54,881 | -42.9% | 0.00% | -40.0% |
| Q1 2022 | $194,000 | -35.8% | 96,059 | -13.9% | 0.01% | -28.6% |
| Q4 2021 | $302,000 | -39.2% | 111,518 | 0.0% | 0.01% | -50.0% |
| Q3 2021 | $497,000 | -33.2% | 111,518 | -13.1% | 0.01% | -41.7% |
| Q2 2021 | $744,000 | +35.5% | 128,322 | +64.1% | 0.02% | +14.3% |
| Q1 2021 | $549,000 | +65.4% | 78,202 | +13.1% | 0.02% | +75.0% |
| Q4 2020 | $332,000 | -30.1% | 69,114 | -15.1% | 0.01% | -58.6% |
| Q3 2020 | $475,000 | +139.9% | 81,398 | +161.7% | 0.03% | +81.2% |
| Q1 2020 | $198,000 | -77.1% | 31,100 | -46.6% | 0.02% | -79.7% |
| Q2 2019 | $866,000 | -30.3% | 58,241 | +16.4% | 0.08% | -34.2% |
| Q1 2019 | $1,242,000 | -48.9% | 50,053 | +92.8% | 0.12% | -76.3% |
| Q2 2017 | $2,431,000 | +198.3% | 25,967 | +102.9% | 0.51% | +232.9% |
| Q1 2017 | $815,000 | +211.1% | 12,800 | +116.9% | 0.15% | +153.3% |
| Q4 2016 | $262,000 | – | 5,900 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |